As the United States looks to reform its healthcare system to provide better value at lower costs, the real challenge is innovating at scale across the country, said Joseph Gifford, MD, chief executive officer of the Providence-Swedish Health Alliance.
As the United States looks to reform its healthcare system to provide better value at lower costs, the real challenge is innovating at scale across the country, said Joseph Gifford, MD, chief executive officer of the Providence-Swedish Health Alliance.
Transcript (slightly modified for readability)
What is the biggest challenge facing American healthcare?
I think the issue here is innovation. It's how do we do things different in our health system that really work for people in a way that they are used to being served in other industries now. I think that is the forefront of innovation: how to treat people in a way they expect to be treated, how to create value for people.
And, ultimately, the really hard part of this is: how do you innovate at scale? This isn't a matter of taking a 10-person primary care group and doing really cool things for people in that really small environment. This is around innovating at scale. How do we really change the healthcare system and [Providence-Swedish Health Alliance's] footprint of 5 states, but also the entire country. How are you really going to create a different healthcare system using real innovation to make the difference. And that's the voyage we're all on.
Health Care Utilization and Cost of Diagnostic Testing for Respiratory Infections
September 17th 2025Syndromic reverse transcriptase–polymerase chain reaction tests for respiratory infections were associated with lower health care resource utilization and costs, implicating potential for improved value in patient care.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More